Adrian Johnson
TLDR:
Key points from the article:
- Armata Pharmaceuticals appointed David House as Senior Vice President of Finance
- David House brings extensive experience in accounting and finance within the life sciences industry
Armata Pharmaceuticals, a biotechnology company focusing on developing bacteriophage therapeutics for antibiotic-resistant infections, announced the appointment of David House as Senior Vice President of Finance. House, a veteran in life sciences accounting and finance, brings a wealth of experience from roles in various life sciences companies. He previously served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., playing a crucial role in the company’s acquisition by Blackstone.
House’s career also includes financial leadership roles at Peregrine Pharmaceuticals, Inc., Avid Bioservices, Inc., and other organizations within the industry. He holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton, and is a California Certified Public Accountant.
Armata Pharmaceuticals is committed to advancing phage therapy for the treatment of antibiotic-resistant bacterial infections. The company is developing a broad pipeline of natural and synthetic phage candidates, with a focus on pathogens like Pseudomonas aeruginosa and Staphylococcus aureus.
As the company continues to advance its programs and prepare for pivotal studies, the addition of David House to the senior team is seen as a strategic move to support long-term success in introducing new anti-infectives to address serious drug-resistant bacterial infections.
